Collaboration to Co-Market shRNA Target Validation Technology
News Sep 16, 2005
Nucleis and RNAx have announced the signing of a non-exclusive co-marketing agreement.
Under the terms of the agreement RNAx provides Nucleis and its customers with in vitro shRNA validation technology to complement their proprietary transgenic animal generation technology, including the “Speedy Mouse® Technology” and vice versa.
The goal of the agreement is to provide both RNAx’ and Nucleis’ customers with both technologies from one source.
RNAx over the past years has developed an automated platform for the validation of siRNAs, shRNAs and genetic targets in a broad variety of commonly used cell lines and primary cells.
Through a number of partnerships with leading European biotech companies, RNAx makes RNAi technology available to many applications during the target discovery and validation process – all the way from gene expression analysis to in vivo validation of more advanced targets.
Nucleis claims that, its Speedy Mouse® Technology is a fast and powerful tool in mice transgenesis: readyto- phenotype mice are obtained in 2 months with 100% chimerism and germline transmission.
This proprietary technology combines the power of patented ES cells (BPES) with the advantages of targeted insertion at the hprt docking site.
Launched in 2003, Speedy Mouse® Technology was proved to fit most research projects from gene over expression, humanized mice to knock down (RNAi) models.
By the end of the year, Nucleis will open a Montreal subsidiary dedicated to R&D program mainly focused on developing innovative type like Speedy Mouse® Technology.
"This agreement gives benefits to both companies: Nucleis will be able to work even more efficiently by using in vitro validated shRNA constructs, whereas RNAx' customers will have direct access to Nucleis' Speedy Mouse® Technology," commented Joerg Poetzsch, CEO of RNAx.
"This partnership substantially extends RNAx’ corporate network in the area of target validation based on RNAi technologies – from the in vitro validation of si- and shRNAs measured by real time PCR, cell based assays, redistribution® assay technology, and target validation in modern transgenic animal technology."
"We are very pleased to collaborate with RNAx which has demonstrated its professionalism and strong expertise in the RNAi field," said Marc Forestier, CEO of Nucleis.
"This collaboration will offer a one-stop shop from design of shRNA molecules to generation of knock down (RNAi) mouse models."
"The combination of the benefits of both RNAx and Nucleis technologies will allow to provide customers with a fast and efficient service for their target validations."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE